摘要
目的观察艾普拉唑7 d三联疗法及10 d序贯疗法根除幽门螺杆菌(Hp)的临床疗效。方法 142例经电子胃镜、RUT检查证实Hp阳性的慢性胃炎患者,随机分成3组。A组予艾普拉唑5 mg+阿莫西林克拉维酸钾0.914 g+呋喃唑酮0.1g,bid,疗程7 d;B组予艾普拉唑5 mg+阿莫西林克拉维酸钾0.914 g,疗程5 d,继之艾普拉唑5 mg+克拉霉素0.5 g+呋喃唑酮0.1g,疗程5 d,共计10 d,每天均给药2次;C组予埃索美拉唑20 mg+阿莫西林克拉维酸钾0.914 g+呋喃唑酮0.1 g,bid,疗程7 d。疗程结束4周后行^(14)C-尿素呼气试验(^(14)C-UBT),观察Hp根除率、症状缓解率及不良反应发生情况。结果 A、B、C组患者症状缓解率比较差异无统计学意义(P>0.05);Hp根除率分别为60%、58.54%和55.26%,经检验P均>0.05。3组患者均无明显不良反应发生。结论 3组用药方案虽能达到良好的症状缓解率,但Hp根除率均未超过60%,低于理想标准。
A/M To evaluate the Helicobacterpylori（Hp） eradication in 7-day triple therapeutic regimen and 10- day sequential therapy with ilaprazole. METHODS A total of 142 Hp-positive patients with chronic gastritis were ran- domly divided into 3 groups： group A, one-week triple therapeutic regimen with ilaprazole 5 ing, amoxicillin and clavu- lanate potassium 0.914 g and furazolidone 0.1 g bid;group B, 10-day sequential therapy with ilaprazole 5 mg bid and amoxicillin and clavulanate potassium 0.914 g bid for 5 d, followed by ilaprazole 5mg bid ＋ clarithremycin 0.5 g bid ＋ furazolidone 0.1 g bid for 5 d; group C, one-week triple therapy with esomeprazole 20 mg, bid, amoxicillin and clavulan- ic acid potassium 0.914 g and furazolidone 0.1 g bid. RESULTS There was no statistical difference in the symptom re- mission rate and the Hp eradication rate between the 3 groups. The Hp eradication rate was 60% ,58.54% and 55.26% respectively. CONCLUSION The 7-day triple therapeutic regimen and 10-day sequential therapy with ilaprazole or es- omeprazole is safe, but not effective in treatment of Hp infection.
出处
《中国临床药学杂志》
CAS
2012年第5期280-283,共4页
Chinese Journal of Clinical Pharmacy
关键词
幽门螺杆菌
艾普拉唑
埃索美拉唑
根除率
三联疗法
序贯疗法
Helicobacter pyori
ilaprazole
esomeprazole
eradiation rate
triple therapy
sequentialtherapy
